Lumos Pharma Financials

Earnings View

Profitability View

Liquidity View

Fundamentals View

Competition View

Lumos Pharma Stock Summary

Lumos Pharma competes with Shattuck Labs, Eliem Therapeutics, Champions Oncology, Century Therapeutics, and Silo Pharma. Lumos Pharma, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for rare diseases. Its lead therapeutic candidate LUM-201 is an oral growth hormone secretagogue ibutamoren, which is in Phase 2 clinical trial for the treatment of pediatric growth hormone deficiency and other rare endocrine disorders. Lumos Pharma operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 32 people.

Lumos Pharma Key Financial Ratios

Lumos Pharma Key Balance Sheet Accounts

Lumos Pharma Key Income Statement Accounts

Lumos Pharma Key Cash Accounts

Lumos Financial Ratios Relationships

Comparative valuation techniques use various fundamental indicators to help in determining Lumos Pharma's current stock value. Our valuation model uses many indicators to compare Lumos Pharma value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Lumos Pharma competition to find correlations between indicators driving Lumos Pharma's intrinsic value. More Info.Lumos Pharma is rated below average in return on equity category among its peers. It also is rated below average in return on asset category among its peers . At this time, Lumos Pharma's Return On Equity is very stable compared to the past year. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Lumos Pharma's earnings, one of the primary drivers of an investment's value.

Lumos Pharma Systematic Risk

Today, most investors in Lumos Pharma Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Lumos Pharma's growth ratios. Consistent increases or decreases in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's growth growth rates may not be enough to decide which company is a better investment. That's why investors frequently use static breakdown of Lumos Pharma growth as a starting point in their analysis.

Along with financial statement analysis, the daily predictive indicators of Lumos Pharma help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Lumos Pharma. We use our internally-developed statistical techniques to arrive at the intrinsic value of Lumos Pharma based on widely used predictive technical indicators. In general, we focus on analyzing Lumos Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Lumos Pharma's daily price indicators and compare them against related drivers.

Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Lumos Pharma. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in population. To learn how to invest in Lumos Stock, please use our How to Invest in Lumos Pharma guide.You can also try the Alpha Finder module to use alpha and beta coefficients to find investment opportunities after accounting for the risk.

Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Lumos Pharma. If investors know Lumos will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Lumos Pharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

The market value of Lumos Pharma is measured differently than its book value, which is the value of Lumos that is recorded on the company's balance sheet. Investors also form their own opinion of Lumos Pharma's value that differs from its market value or its book value, called intrinsic value, which is Lumos Pharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Lumos Pharma's market value can be influenced by many factors that don't directly affect Lumos Pharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Lumos Pharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if Lumos Pharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Lumos Pharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.